Rhumbline Advisers Xenon Pharmaceuticals Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 29 shares of XENE stock, worth $1,110. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29
Previous 29
-0.0%
Holding current value
$1,110
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding XENE
# of Institutions
212Shares Held
70.2MCall Options Held
88.3KPut Options Held
28.8K-
Avoro Capital Advisors LLC New York, NY5.67MShares$217 Million3.36% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.6MShares$176 Million1.77% of portfolio
-
Wellington Management Group LLP Boston, MA3.84MShares$147 Million0.03% of portfolio
-
Braidwell LP Stamford, CT2.71MShares$104 Million3.02% of portfolio
-
Commodore Capital LP New York, NY2.7MShares$103 Million9.03% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.39B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...